Aprepitant alleviates acute lung injury in a rat model of hepatic ischemia-reperfusion via NLRP3/IL-1β signaling pathway.

ABSTRACT: Hepatic ischemia reperfusion (HIR) injury is a complication that complicates major liver surgeries and contributes to significant hepatic and remote organs damage. Aprepitant (Ap), a neurokinin-1 receptor (NK-1R) antagonists, is an antiemetic commonly used in preventing chemotherapy-induced nausea and vomiting. This study aimed to evaluate the potential protective effect of Ap against acute lung injury (ALI) associated with HIR, utilizing the Pringle maneuver to induce 30 min of hepatic ischemia followed by 1 h of reperfusion, while targeting the NLRP3/IL-1β signaling pathway. Serum alanine transaminase (ALT), aspartate transaminase (AST), Lung malondialdehyde (MDA), total antioxidant capacity (TAC), reduced glutathione (GSH), tumor necrosis factor-alpha (TNF-α), caspase-3 levels, NOD-, LR

SUBMITTER: Abdelzaher WY 

PROVIDER: S-EPMC12627803 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature